Revival of the Amsterdam Life Sciences Café

The Amsterdam Economic Board and EY are pleased to announce the revival of the Amsterdam Life Sciences Café. Inspired by the moving of the European Medicines Agency to Amsterdam, we kindly invite you to attend a debate on drug regulations and its impact on new drug discovery and development.

Drs. Willem van Weperen, VP at Amicus Therapeutics, will give a brief introduction on the game changing work in the region that is performed around personalized cancer treatments and rare diseases.

Dr. Carla Herberts of the Dutch Medicines Evaluation Board (CBG) will highlight regulatory aspects around Advanced Therapy Medicinal Products (ATMPs) and explain how the quality, risks and efficacy of these high potential therapies are assessed. ATMPs are medicinal products based on genes, cells or tissues.

Both speakers will have a conversation on how regulatory sciences and breakthrough medical interventions are connected, and how this will look like in the future. As an attendee, you are invited to actively join the discussion here as well.

The location Café Restaurant Polder offers an attractive, informal atmosphere, but spaces are limited, so do not wait too long to register. The Amsterdam Life Sciences Café is free of charge.

We look forward to seeing you!

About Amsterdam Life Sciences café

The Amsterdam Economic Board together with EY, organizes Life Sciences cafés four times a year. These meet-ups are aimed at bringing together health innovators and professionals, the business community, researchers and knowledge institutes in the field of health and prevention. It is designed to share knowledge and new research and innovative applications. The next Life Sciences Cafés are on September 20th and November 22nd.

30 April 2018

Read more about

Contact us

Want to keep up to date?

Get the best regional news and events (in Dutch) via the Board Update newsletter

Share this news

#slimgroengezond

Want to read more articles like this one?
Follow us daily on LinkedIn and sign up for our Board Update.

Read more